https://www.selleckchem.com/pr....oducts/lonidamine.ht
In cases of non-small-cell lung cancer (NSCLC), molecular-targeted therapy has shown remarkable improvements in the survival and safety compared with conventional chemotherapy. Recently, the tropomyosin receptor kinase (TRK) inhibitors entrectinib and larotrectinib were approved in the United States, Europe, and elsewhere for patients with a neurotrophic tropomyosin-related kinases (NTRK) gene fusion-positive solid tumors, including NSCLC. Furthermore, next-generation TRK inhibitors that are sensitive to certain secondary mutations m
Like
Comment
Share
